MaxCyte, Inc. (MXCT) vs Zomedica Corp. (ZOMDF)
MaxCyte, Inc. and Zomedica Corp. are both Medical Devices companies. MaxCyte, Inc. is the larger, with a market value of $122.8M against $95.4M — 1.3× the size. Zomedica Corp. grew revenue faster over the last twelve months: 30.1% against −13.2%. Zomedica Corp. has the higher net margin (−51.4% vs −114.8%) and the higher return on invested capital (−20.5% vs −49.2%). Across the 16 metrics below, Zomedica Corp. leads on 12 and MaxCyte, Inc. on 4.
Valuation
Profitability
| Metric | MXCT | ZOMDF | Medical Devices median |
|---|---|---|---|
| Gross margin | 79.23% | 65.44% | 56.01% |
| Operating margin | (134.59%) | (56.28%) | (15.03%) |
| Net margin | (114.77%) | (51.39%) | (20.40%) |
| Free cash flow margin | (76.14%) | (40.75%) | (7.24%) |
| Return on equity | (20.39%) | (16.29%) | (15.32%) |
| Return on assets | (17.62%) | (14.88%) | (19.72%) |
| Return on invested capital | (49.23%) | (20.54%) | (10.33%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack